radioactive drug

May 31, 2017May 31, 2017

European Union Approves Axumin as Imaging Agent for Detecting Prostate Cancer Recurrences

News

The European Union has granted marketing authorization to Axumin, an injectable radioactive agent used to detect prostate cancer that has recurred. High levels or PSA, or prostate specific antigen in ... Read more

June 6, 2016June 6, 2016

FDA Approves Diagnostic Imaging Agent Axumin for Recurrent Prostate Cancer

News

The US Food and Drug Administration (FDA) has recently approved Axumin, an injectable radioactive diagnostic agent used to detect recurrent prostate cancer. Axumin (marketed by Blue Earth Diagnostics, Ltd., Oxford, ... Read more